In conclusion, our study highlights the potential of pre-screening for BRG1 status in wt-EGFR NSCLC patients to enable personalized treatment strategies to mitigate treatment-related resistance and enhance therapeutic outcomes. Here, SMARCA4 is linked to non-small cell lung carcinoma.